New cancer clinical trial: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Published on: April 30, 2018 at 12:00PM
Condition:   Prostate Cancer
Interventions:   Drug: 177Lu-PSMA-617;   Other: Best supportive/best standard of care
Sponsor:   Endocyte
Not yet recruiting
https://ift.tt/2I3WaDX